AstraZeneca Plc’s Chief Executive Officer Pascal Soriot wants to move the drugmaker’s stock listing to the US, the Times reported, in what would be another sign of the UK’s waning status as a magnet for global capital. The pharma chief is frustrated at the UK’s regulatory regime for drugs and concerned that the country’s life sciences industry is falling behind the US and China, the newspaper said, citing people familiar with the situation. Soriot has also discussed moving AstraZeneca’s domicile, the Times said.
